{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:37Z","timestamp":1792039597818,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000351","name":"British Lung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000362","name":"Asthma and Lung UK","doi-asserted-by":"publisher","award":["MPG16-7"],"award-info":[{"award-number":["MPG16-7"]}],"id":[{"id":"10.13039\/501100000362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109624","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:57:14Z","timestamp":1789495034000},"page":"109624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discordance in pleural mesothelioma response classification and modelling of impact on clinical trials"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7751-0111","authenticated-orcid":false,"given":"Gordon W.","family":"Cowell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-3878","authenticated-orcid":false,"given":"Joshua","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0873-3283","authenticated-orcid":false,"given":"Colin","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Stobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-0633","authenticated-orcid":false,"given":"Andrew","family":"Papanastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2462-1488","authenticated-orcid":false,"given":"Selina","family":"Tsim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-6641","authenticated-orcid":false,"given":"Kevin G.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109624_b0005","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109624_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109624_b0015","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109624_b0020","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1118\/1.1688211","article-title":"Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques","volume":"31","author":"Armato","year":"2004","journal-title":"Med. Phys."},{"key":"10.1016\/j.lungcan.2026.109624_b0025","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s00330-018-5887-z","article-title":"Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma","volume":"29","author":"Li","year":"2019","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.lungcan.2026.109624_b0030","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0169-5002(18)30090-4","article-title":"64 an update regarding the prediction of resistance to chemotherapy using somatic copy number variation in mesothelioma (PRISM) study","volume":"115","author":"Blyth","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109624_b0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up \u2020","volume":"33","author":"Popat","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109624_b0040","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109624_b0045","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.ejca.2012.05.018","article-title":"Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma","volume":"48","author":"Blayney","year":"2012","journal-title":"Eur. J. Cancer (Oxford England: 1990)"},{"key":"10.1016\/j.lungcan.2026.109624_b0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1634\/theoncologist.2016-0121","article-title":"Validation of progression-free survival as a surrogate endpoint for overall survival in malignant mesothelioma: analysis of cancer and leukemia group B and north central cancer treatment group (alliance) trials","volume":"22","author":"Wang","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2026.109624_b0055","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/thoraxjnl-2021-217808","article-title":"Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria","volume":"77","author":"Kidd","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.lungcan.2026.109624_b0060","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","article-title":"North American multicenter volumetric CT study for clinical staging of malignant pleural mesothelioma: feasibility and logistics of setting up a quantitative imaging study","volume":"11","author":"Gill","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109624_b0065","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.athoracsur.2016.06.069","article-title":"A multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma","volume":"102","author":"Rusch","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109624_b0070","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jtho.2018.05.003","article-title":"Revised modified RECIST criteria in malignant pleural mesothelioma (version 1.1): a step forward in a long race","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109624_b0075","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1200\/JCO.2010.33.7071","article-title":"Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes","volume":"29","author":"Oxnard","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109624_b0080","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/JTO.0000000000000211","article-title":"Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions","volume":"9","author":"Armato","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109624_b0085","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170405","article-title":"Influence of lung nodule margin on volume- and diameter-based reader variability in CT lung cancer screening","volume":"91","author":"Han","year":"2018","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.lungcan.2026.109624_b0090","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/ejcts\/ezv422","article-title":"Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma","volume":"49","author":"Kircheva","year":"2016","journal-title":"Eur. J. Cardio-Thoracic Surg.: Off. J. Eur. Assoc. Cardio-Thoracic Surg."},{"key":"10.1016\/j.lungcan.2026.109624_b0095","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00146110","article-title":"Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?","volume":"38","author":"Frauenfelder","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2026.109624_b0100","first-page":"S1115","article-title":"1910MO - ARTIMES: automated response evaluation to treatment in mesothelioma","author":"Lipman","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109624_b0105","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.5858\/arpa.2016-0073-OA","article-title":"Dataset for reporting of malignant mesothelioma of the pleura or peritoneum: recommendations from the international collaboration on cancer reporting (ICCR)","volume":"140","author":"Churg","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.lungcan.2026.109624_b0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13244-023-01408-7","article-title":"Implementation of structured reporting in clinical routine: a review of 7 years of institutional experience","volume":"14","author":"Jorg","year":"2023","journal-title":"Insights Imaging"},{"key":"10.1016\/j.lungcan.2026.109624_b0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.11.010","article-title":"The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy","volume":"103","author":"Tsim","year":"2017","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.lungcan.2026.109624_b0120","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma\u2014RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109624_b0125","article-title":"Real-world outcomes of patients with malignant pleural mesothelioma receiving a combination of ipilimumab and nivolumab as first- or later-line treatment","volume":"5","author":"Schmid","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109624_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107440","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109624_b0135","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/bjc.2015.62","article-title":"The South West Area mesothelioma and pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication","volume":"112","author":"Hooper","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109624_b0140","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:08:22Z","timestamp":1792037302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"alternative-id":["S0169500226006859"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109624","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discordance in pleural mesothelioma response classification and modelling of impact on clinical trials","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109624"}}